MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Why Did Humacyte Launch a $50 Million Public Offering

14 hours ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does Hitek Global's Recent $8 Million Offering Mean for Investors

1 week ago

What Does Getty Realty's $131 Million Stock Offering Mean for Investors

3 months ago

What Does NRx Pharmaceuticals' Recent $22.3 Million Offering Mean for Investors

6 days ago

What's Behind Adam Portnoy's Massive $50 Million Bet on Service Properties Trust

2 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte priced a public offering of 47.6M shares at $1.05/share, expecting $50M in gross proceeds, to close around June 12.

HUMA

Stock News•2 days ago

Tango Therapeutics Announces Proposed $500 Million Public Offering

Tango Therapeutics launched a $500M public stock offering, with an underwriter option for an additional $75M, to fund its clinical-stage precision cancer pipeline.

TNGX

Stock News•5 days ago

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Humacyte, Inc. faces a shareholder inquiry into whether insiders breached fiduciary duties. The firm invites shareholders to discuss legal rights and options on a contingent fee basis.

HUMA

Stock News•1 months ago

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Humacyte, Inc. (HUMA) shares fell 1.14% to close at $0.70 in the most recent trading session. The decline occurred despite broader market gains, reflecting localized downward pressure on the stock.

HUMA